bioAffinity Technologies, Inc. (BIAF) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $2.81. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Valuation: BIAF trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $6M, +17617.5%/yr average growth. Net income is $15M (loss), growing at -25.4%/yr. Net profit margin is -242% (negative). Gross margin is 23.2% (-67.1 pp trend).
Balance sheet: total debt is $1M against $7M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 2.6 (strong liquidity). Debt-to-assets is 10.6%. Total assets: $11M.
Analyst outlook: 0 / 1 analysts rate BIAF as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 14/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).
